[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653543":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":11,"studyPopulation":11,"armGroups":41,"interventions":58,"overallOfficials":70,"centralContacts":75,"locations":11,"responsibleParty":80,"collaborators":11,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":11,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":11,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":11,"overallStatus":102,"whyStopped":11,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":11},{"fullName":5,"class":6},"Surmount Services, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":11},[9,13,15,17,19],{"measure":10,"description":11,"timeFrame":12},"Plasma PK parameters Cmax",null,"From Day 1 to Day 14 (EOS visit)",{"measure":14,"description":11,"timeFrame":12},"Plasma PK parameters- Tmax",{"measure":16,"description":11,"timeFrame":12},"Plasma PK parameters- AUC0-last",{"measure":18,"description":11,"timeFrame":12},"Serum concentration of adalimumab",{"measure":20,"description":11,"timeFrame":12},"Serum concentration of guselkumab",[22,24,26,28,30,33],{"measure":23,"description":11,"timeFrame":12},"Incidence of TEAEs",{"measure":25,"description":11,"timeFrame":12},"Incidence of SAEs",{"measure":27,"description":11,"timeFrame":12},"Number of participants with abnormal vital signs",{"measure":29,"description":11,"timeFrame":12},"Number of participants with abnormal Physical examination findings",{"measure":31,"description":11,"timeFrame":32},"Number of participants with abnormal ECG readings","Days 1, 3,7 and day 14 (EOS visit)",{"measure":34,"description":11,"timeFrame":32},"Number of participants with abnormal Laboratory findings",{"allocation":36,"interventionModel":37,"interventionModelDescription":11,"primaryPurpose":38,"observationalModel":11,"timePerspective":11,"maskingInfo":39},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":40,"maskingDescription":11,"whoMasked":11},"NONE",[42,47,51,55],{"label":43,"type":44,"description":11,"interventionNames":45},"Guselkumab","EXPERIMENTAL",[46],"Drug: Guselkumab",{"label":48,"type":44,"description":11,"interventionNames":49},"Guselkumab + SDL-001 Formulation",[46,50],"Drug: SDL-001",{"label":52,"type":44,"description":11,"interventionNames":53},"Adalimumab",[54],"Drug: Adalimumab",{"label":56,"type":44,"description":11,"interventionNames":57},"Adalimumab + SDL-001 Formulation",[54,50],[59,63,66],{"type":60,"name":52,"description":61,"armGroupLabels":62,"otherNames":11},"DRUG","Single intracolonic administration of adalimumab",[52,56],{"type":60,"name":43,"description":64,"armGroupLabels":65,"otherNames":11},"Single intracolonic administration of guselkumab",[43,48],{"type":60,"name":67,"description":68,"armGroupLabels":69,"otherNames":11},"SDL-001","SDL-001 is a formulation administered intracolonically with monoclonal antibodies",[56,48],[71],{"name":72,"affiliation":73,"role":74},"Christopher Moller","University of the Sunshine Coast Clinical Trials, Maroochydore, QLD","PRINCIPAL_INVESTIGATOR",[76],{"name":72,"role":77,"phone":78,"phoneExt":11,"email":79},"CONTACT","+61 7 5409 8659","cmoller@usc.edu.au",{"type":81,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100653543","phase-1-a-study-to-investigate-how-well-an-intracolonic-formulation-of-two-monoclonal-antibodies-is-tolerated-in-healthy-participants-and-the-ability-for-the-antibodies-to-be-taken-up-by-the-body-via-the-colon-100653543",false,"NCT07788807","A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon","An Open-label, Phase 1, Pharmacokinetic Study of a Single Dose of Transcolonically Administered Adalimumab and Guselkumab in Healthy Adult Participants","Inclusion Criteria:\n\n* In good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and\u002For before the first administration of the study drug, at the discretion of the PI or designee.\n* Body mass index (BMI) between ≥ 18.0 and ≤ 32.0 kg\u002Fm2 and weight ≥ 50 and ≤ 100 kg.\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant, or currently breastfeeding\n* Current or recent clinically significant infection\n* Any history of inflammatory bowel disease\n* History of malignancy, except for non-melanoma skin cancer excised",true,"ALL","18 Years","45 Years",{"count":94,"type":95},18,"ESTIMATED","INTERVENTIONAL",[98],"PHASE1","This is a proof-of-concept study to investigate whether antibodies (guselkumab and adalimumab) delivered directly to the colon can enter the systemic circulation. The study endpoints chosen for this study are commonly used for evaluating the safety, tolerability, and PK of single doses of IPs. No interim analysis is planned.",[101],"Healthy Subjects","NOT_YET_RECRUITING","2026-08-20",{"date":105,"type":106},"2026-08-26","ACTUAL",{"date":108,"type":95},"2026-09-15",{"date":110,"type":95},"2026-12-30",{"name":5,"class":6}]